Drug intelligence / Profile preview

YAZFlex

Development stage: Unknown
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral

Overview

**YAZFlex** is a flexible extended-cycle combined oral contraceptive (COC) containing drospirenone (3 mg), a synthetic progestogen with antimineralocorticoid and antiandrogenic properties, and ethinyloestradiol (20 μg as betadex clathrate), a synthetic estrogen. It prevents pregnancy primarily through ovulation inhibition, cervical mucus thickening, and endometrial changes, while offering additional benefits like reduced menstrual bleeding, less painful periods, and treatment of moderate acne vulgaris via androgen suppression. Developed as a variant of the conventional 24/4 regimen YAZ, it provides dosing flexibility for extended use.[3]

Brand names: YAZFlex
Other names: YAZ Flex

Targets

MR (Mineralocorticoid receptor)ER (Estrogen receptor)PR (Progesterone receptor)AR (Adrenergic receptors)

Beyond the preview

Go deeper on YAZFlex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YAZFlex.

Explore the full profile